Every lawful way to get a GLP-1 in the United States starts with a prescription. After that there are three ways to pay: your insurance, a manufacturer’s own cash price, or the federal Medicare GLP-1 Bridge at $50 a month. The lowest published cash price is $149 a month for Tablet, 1.5 mg. Starting strength. The label moves off it after 30 days.
Source: 7 routes, priced from manufacturer terms read 2026-08-12
What matters first
Prescription
Required for every lawful US route
Routes checked
7
Lowest published cash row
$149 for Tablet, 1.5 mg
FDA warning-letter matches
358
Find current care
Compare clinics before you book
See the service, care team, visit type, price state, license record and current appointment path. Booking finishes on the clinic’s website.
The clinic finder and this access reference do different jobs. The finder compares current care records. What follows explains each prescription and payment route, its published price, who it leaves out and what FDA’s enforcement record says.
The routes that exist
Seven of them, and the last two are not what they look like. Each card answers the same four questions, so you can read down a column instead of across a page.
A prescription from a clinician you see
Open
The ordinary route. A doctor, nurse practitioner or physician assistant assesses you and writes a prescription, and a pharmacy fills it.
Prescription
Yes, and it is not optional. Federal law makes every drug on this site prescription-only, which means it cannot lawfully be sold to you without one.
What is published about cost
Whatever your plan charges, plus the manufacturer’s savings card if your plan covers the drug. The cards take most people to about $25 a month.
Who it does not work for
Nobody, in principle. In practice the delay is getting an appointment, and plans differ wildly on whether they cover a GLP-1 for weight at all.
A prescription from a telehealth service
Conditions apply
You fill in a questionnaire or take a video call, a clinician the service works with writes the prescription, and a pharmacy ships it.
Prescription
Yes. The law does not treat a telehealth prescription differently. What changes is who you are talking to and what they are selling.
What is published about cost
Set by the service, and it usually bundles the visit, the drug and the follow-up into one monthly fee. Those fees are not published in one place and they move.
Who it does not work for
Anyone the service decides not to take. Some will not work with insurance at all, so the fee is on top of whatever else you pay.
In FDA’s letters
This is where FDA’s letters land hardest. The largest single group in the published research is telehealth companies, and the two things FDA describes most are claims the advertising could not support and drugs sold without approval.
Buying direct from the manufacturer
Conditions apply
Eli Lilly and Novo Nordisk both sell some of their own products for cash, through their own pharmacies, at prices they publish.
Prescription
Yes. Buying direct changes who ships the box, not whether a prescription is needed.
What is published about cost
Published, dose by dose, on the manufacturer’s own site. It is the only cash lane on this page where the price is written down and dated.
Who it does not work for
Not everything is in it. Lilly publishes a full cash ladder for Zepbound and none at all for Mounjaro, and Novo Nordisk prices its starting strengths well below the ones people settle on.
In FDA’s letters
Both manufacturers have received FDA warning letters about how they advertised these drugs. We include those letters under the same rules used for every other company.
Your own insurance
Conditions apply
A commercial plan covers the drug, you pay a copay, and a manufacturer savings card usually covers most of what is left.
Prescription
Yes, and the plan often wants more: a prior authorization, a documented reason, sometimes a weight or a diagnosis.
What is published about cost
About $25 a month on every card here, while the card lasts. Each card caps what it will pay in a month and in a year, and the caps differ by product.
Who it does not work for
Every one of these cards excludes anyone on Medicare, Medicaid, TRICARE or VA coverage. The exclusions are quoted word for word on each product’s cost page, because that is where a reader loses money.
Medicare’s GLP-1 Bridge
Conditions apply
A federal program that puts some GLP-1 drugs at a fixed monthly price for people with Medicare drug coverage. It runs on a stated end date.
Prescription
Yes, plus a prior authorization, and your prescriber has to certify a diet and exercise program as well.
What is published about cost
$50 a month. None of it counts toward the Part D out-of-pocket limit, and there is no low-income subsidy on it.
Who it does not work for
It covers three named products and no others. It also rules out anyone whose reason for taking a GLP-1 is type 2 diabetes, which puts Ozempic and Mounjaro outside it entirely.
A compounded copy from a pharmacy
Basis ended
A pharmacy mixes its own version rather than dispensing an approved product. Nobody checks it for safety, strength or quality first.
Prescription
Yes. A compounded drug is still a prescription drug, and under section 503A it needs a prescription with your name on it.
What is published about cost
Whatever the seller charges. There is no published price for a compounded preparation because there is no product to publish one for.
Who it does not work for
The legal basis for large-scale compounding of these two drugs was the shortage listing, and both shortages ended. The windows closed in March and May 2025.
In FDA’s letters
Compounding pharmacies appear in the published research in their own right. FDA inspected the places that mixed the drug, and several of those letters describe what it found there.
A site selling it as a research chemical
No lawful route
A website sells a vial of powder labeled for laboratory use, usually with a line saying it is not for human consumption.
Prescription
Nobody asks you for one, and that is the tell. A seller who does not need a prescription is not selling you a medicine, whatever the vial says.
What is published about cost
Cheap, and the price is the product. Nothing about what is in the vial is established by anyone: not the strength, not the purity, not that it is the drug on the label.
Who it does not work for
There is no lawful route here to a person. These are unapproved drugs, and selling one to a consumer in the United States is what most of FDA’s letters to these sites are about.
In FDA’s letters
A large block of the published research is exactly this: sites offering unapproved drugs to United States consumers over the internet. Several letters name a web address rather than a company.
What the cheapest route actually costs
The lowest published cash price for any of these drugs comes from the manufacturer itself, not from a pharmacy counter. It is a real number with a condition attached, and the condition is the part that costs money.
NovoCare Pharmacy self-pay — lowest published row
$149 for Tablet, 1.5 mg. Starting strength. The label moves off it after 30 days.
A month here means 28 days and one box of four pens for the shot, or 30 days and one bottle of 30 tablets. Terms read 2026-08-12, and they change without notice.
The number underneath every price
CMS runs a weekly survey of what pharmacies report paying to buy a drug. It is not a price anyone is offered and nobody is charged it. It is the floor beneath the counter.
What a pharmacy pays — ZEPBOUND 15 MG/DOSE (60 MG/2.4 ML) KWIKPEN
$670.23 a month for the KwikPen. $279.26 per mL × 2.4 mL a KwikPen × 1 KwikPen = $670.23.
That covers 28 days and one KwikPen, which holds four weekly doses. The figure took effect 22 July 2026 and the file is republished weekly.
Set those two side by side and the manufacturer’s own direct price sits below what a pharmacy reports paying for the same box. Both are published, both carry their own date, and what settles in between them is not published by anyone. The full working, per product, is on the cost pages.
Every ladder, every exclusion quoted word for word, and every retrieval date lives at the cost record. Prices stay on those pages so there is only one place to update them.
What is lawful right now
One route changes with the calendar. Compounding a copy of a drug you can already buy is barred, and these two drugs escaped that bar only while they sat on FDA’s shortage list. So the list decides. Neither semaglutide nor tirzepatide is on FDA’s shortage list today, checked 14 August 2026.
FDA declared the tirzepatide shortage over on 19 December 2024 and the semaglutide shortage over on 21 February 2025. The windows to keep compounding closed during March and May 2025. The dated documents are in the compounding record.
Status comes from FDA’s drug shortage database on the date shown. The list changes daily. openFDA, read 2026-08-14.
The part nobody else publishes
FDA writes to companies it believes are breaking the law, and it publishes the letters. Of the 3,651 warning letters FDA has published, 141 mention semaglutide and 109 mention tirzepatide. Most are addressed to telehealth services, compounding pharmacies and websites.
A warning letter is FDA telling a company what the agency believes it found. It is not a court ruling and not proof that anyone was harmed.
A seller missing from this list is a seller FDA has published no letter about. That is all it means. Many sites selling these drugs are not registered with FDA at all, so nothing they do produces a letter in the first place.
The 150 letters issued since 12 August 2024 are listed with FDA’s own subject line, both of its dates, its close-out column and a link to its own page, at the enforcement record.
By molecule
The routes differ by drug, and one of these three has none at all.
Letter counts are FDA’s own search, read 12 August 2026. They count letters that mention the drug anywhere in the text, which is not always what the letter was about.
Outside the United States
Country rules that materially change the answer
These are not translated copies. We add a country only when its official sources change the price, access route, product status, or legal rules a reader needs to know.
14 peptide entries appear in Health Canada’s 9 April 2026 warning list.
Questions people actually ask
Can I get a GLP-1 without a prescription?
Not lawfully. Federal law makes these drugs prescription-only, so a seller who does not ask for one is not selling an approved medicine. That is what most of FDA’s letters to internet sellers are about.
Is buying from a telehealth service legal?
A telehealth prescription is a prescription, and the law does not treat it differently. What differs is what the service sells and what it says about it. FDA has written to a large number of these companies about both.
What is the cheapest way to get one?
Of the prices anyone publishes, the manufacturer’s own cash lane is the lowest, and the advertised figure is usually a starting dose rather than a monthly rate. Every ladder is on the cost record with the manufacturer’s conditions attached.
Does Medicare cover any of this?
Medicare GLP-1 Bridge covers three named products at $50 a month, and it runs to 2027-12-31. It rules out anyone whose reason for a GLP-1 is type 2 diabetes. Every manufacturer savings card excludes people on Medicare entirely.
A seller is not in FDA’s list. Does that mean it is fine?
A seller missing from this list is a seller FDA has published no letter about. That is all it means. Many sites selling these drugs are not registered with FDA at all, so nothing they do produces a letter in the first place.
Can this site help me find a clinic?
Yes, where a clinic market has enough current records to publish. You can compare the service, care team, visit type, license record and appointment path, then book on the clinic’s own website. HealthspanLedger does not diagnose, prescribe or book the visit.
3Scope and reviewWhat can change, what remains unknown, and how the information is checked
What remains unknown
These get asked a lot. Saying why there is no page for them is more useful than a page that exists because the question is popular. Where part of one of them can be answered from a published file, the refusal points at the page that answers it.
Where is the nearest clinic or pharmacy?
We hold no local data of any kind — no addresses, no opening hours, nothing about who is taking patients. Google answers this in the map panel above the results, from data we do not have and could not check. What we can answer is what being near anywhere changes about the drug, which turns out to be three things, and the drug is not one of them.
Answering that means ranking sellers, and a ranking is the thing sellers pay to move. Every page on this site would be worth less the day that started. What we can show is FDA’s own page, which is not for sale.
Where can I buy it without a prescription?
There is no lawful answer. These are prescription drugs, and a seller who skips that step is selling an unapproved product.
Is a particular seller safe?
We cannot know, and neither can anyone else from the outside. An FDA letter documents a specific problem at a specific time; it does not prove that every other part of a company is acceptable.
What can change locally
This is a description of routes that exist and prices that are published. It is not advice about which one to take, and it is not medical or legal advice.
Only a licensed clinician can write a prescription. Nothing here helps anyone get a prescription.
Prices move. Every figure on the cost pages carries the date its source was read, and manufacturer terms change without notice.
Insurance is not covered in any depth, because plans differ so much that a general statement about coverage would be wrong for most readers.
State law is not covered. Pharmacy practice and telehealth rules are set state by state and they differ.
How we checked these details
JM
Medically reviewed by Jennifer Montecillo, MD· non-practicing medical reviewer
Reviewed 2026-08-12
No seller is named as a place to buy, ranked or linked here, and no listing on this site is for sale. Prices come from the manufacturer’s own terms or from a federal file, each with the date it was read. The wider rules are in the sourcing methodology and the editorial policy; corrections go to contact@healthspanledger.com.
A warning letter is FDA telling a company what the agency believes it found. It is not a court ruling and not proof that anyone was harmed.
Companies answer these letters and matters get resolved. Where FDA has published a close-out letter, the date sits beside the letter. FDA issues one only after it has checked that the fix was actually made rather than promised.
An empty close-out column does not mean a matter is open. FDA says it issues no close-out letter at all where a violation is by its nature not correctable, and the program only covers letters issued from September 2009 onward.
A seller missing from this list is a seller FDA has published no letter about. That is all it means. Many sites selling these drugs are not registered with FDA at all, so nothing they do produces a letter in the first place.
The search reads FDA’s full text, so a letter appears here if the drug is mentioned anywhere in it. That is not always what the letter was about.
This is a dated snapshot of a weekly-moving record, not a live lookup.
Keep reading
What each product costs— every published ladder, with the manufacturer’s own exclusions quoted.